Show simple item record

dc.contributor.authorMikhael, Joseph
dc.contributor.authorBelhadj-Merzoug, Karim
dc.contributor.authorHulin, Cyrille
dc.contributor.authorVincent, Laure
dc.contributor.authorMoreau, Philippe
dc.contributor.authorGasparetto, Cristina
dc.contributor.authorPour, Ludek
dc.contributor.authorSpicka, Ivan
dc.contributor.authorVij, Ravi
dc.contributor.authorZonder, Jeffrey
dc.contributor.authorAtanackovic, Djordje
dc.contributor.authorGabrail, Nashat
dc.contributor.authorMartin, Thomas G
dc.contributor.authorPerrot, Aurore
dc.contributor.authorBensfia, Samira
dc.contributor.authorWeng, Qilong
dc.contributor.authorBrillac, Claire
dc.contributor.authorSemiond, Dorothée
dc.contributor.authorMacé, Sandrine
dc.contributor.authorCorzo, Kathryn P
dc.contributor.authorLeleu, Xavier
dc.date.accessioned2021-05-17T14:29:29Z
dc.date.available2021-05-17T14:29:29Z
dc.date.issued2021-05-12
dc.identifier.urihttp://hdl.handle.net/10713/15660
dc.description.urihttps://doi.org/10.1038/s41408-021-00478-4en_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8116334/en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofBlood Cancer Journalen_US
dc.subjectisatuximaben_US
dc.subject.meshMultiple Myeloma--drug therapyen_US
dc.titleA phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumaben_US
dc.typeArticleen_US
dc.identifier.doi10.1038/s41408-021-00478-4
dc.identifier.pmid33980831
dc.source.volume11
dc.source.issue5
dc.source.beginpage89
dc.source.endpage
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record